Sunshine Biopharma Announces Publication Of Significant Coronavirus Research Results In The Journal Of Medicinal Chemistry

Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18%

Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both submicromolar potency and animal model efficacy

XR8-23 (Compound 10) showed significant drug accumulation in lung of mice and favorable pharmacokinetic properties

Research was conducted in collaboration with the University of Arizona

FORT LAUDERDALE, FL / ACCESSWIRE / September 4, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor with submicromolar potency and in vivo efficacy in a mouse model of SARS-CoV-2 infection. This peer-reviewed study marks an important milestone for Sunshine Biopharma in its effort to develop an effective treatment for SARS-CoV-2 infection.